trending Market Intelligence /marketintelligence/en/news-insights/trending/kvttdvtaHkH3N8eGal8Bcw2 content esgSubNav
In This List

US court upholds insider trading lawsuit against Valeant, investor Ackman

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


US court upholds insider trading lawsuit against Valeant, investor Ackman

A U.S. District court tentatively denied a request by Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman to dismiss claims of insider trading by Allergan Inc.'s shareholders, Bloomberg News reported.

The shareholders of Allergan Inc., which is a part of Allergan plc, alleged that Ackman bought their shares while he secretly knew that Valeant was planning a hostile bid.

Judge David Carter of the U.S. District Court, Central District of California, Santa Ana, issued the tentative ruling and the defendants will likely face a jury trial in January 2018, the news outlet reported.

According to Bloomberg News, the case depends on whether in 2014, Ackman's Pershing Square Capital Management and Valeant planned to take their offer directly to the Botox maker's shareholders instead of negotiating a deal with management.

The case also depends on whether Pershing Square's efforts to buy Allergan were genuine or if it was just helping to make Valeant's bid easier, Bloomberg News reported.